Subsequently, we assessed the prognostic relevance of polymorphisms in CCND2, CDKN1B, CDKN2A, CDKN2B, EML4, HNF1A, ID3, IGF1, IGF1R, IGF2, INHBA, INSR, IRS1, IRS2, and TCF7L2 in a cohort of 99 consecutive metastatic non‐diabetic colon cancer patients with favorable clinical conditions. The gene discussed is CCND2; the disease is malignant colon neoplasm.